Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saad S Kenderian

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 17, 2017
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the ShelfMarco Ruella, Saad S Kenderian
Immunotherapy|September 13, 2024
Bioengineering MSCs for untapped therapeutic potentialOlivia Sirpilla, Saad S Kenderian
Current Opinion in Hematology|November 26, 2019
Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapiesRosalie M Sterner, Saad S Kenderian
Transplantation|August 13, 2016
The Microbiome and Immune Regulation After TransplantationJames H Tabibian, Saad S Kenderian
Journal of Cellular Immunology|August 11, 2020
CRISPR Taking the Front Seat in ImmunotherapySaad S Kenderian, Andrew D Badley
Frontiers in Immunology|September 28, 2020
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel TherapiesElizabeth L Siegler, Saad S Kenderian
Leukemia|August 25, 2023
Who wins the combat, CAR or TCR?Kun Yun, Elizabeth L Siegler, Saad S Kenderian
Mayo Clinic Proceedings|March 6, 2021
In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019Zelalem Temesgen, Saad S Kenderian, Andrew D Badley
Methods in Molecular Biology (Clifton, N.J.)|July 24, 2017
Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid LeukemiaSaad S Kenderian, Carl H June, Saar Gill
Clinical Hematology International|January 7, 2021
CART Cell Toxicities: New Insight into Mechanisms and ManagementAnas Zahid, Elizabeth L Siegler, Saad S Kenderian
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 17, 2017
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the ShelfMarco Ruella, Saad S Kenderian
Immunotherapy|September 13, 2024
Bioengineering MSCs for untapped therapeutic potentialOlivia Sirpilla, Saad S Kenderian
Current Opinion in Hematology|November 26, 2019
Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapiesRosalie M Sterner, Saad S Kenderian
Transplantation|August 13, 2016
The Microbiome and Immune Regulation After TransplantationJames H Tabibian, Saad S Kenderian
Journal of Cellular Immunology|August 11, 2020
CRISPR Taking the Front Seat in ImmunotherapySaad S Kenderian, Andrew D Badley
Frontiers in Immunology|September 28, 2020
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel TherapiesElizabeth L Siegler, Saad S Kenderian
Leukemia|August 25, 2023
Who wins the combat, CAR or TCR?Kun Yun, Elizabeth L Siegler, Saad S Kenderian
Mayo Clinic Proceedings|March 6, 2021
In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019Zelalem Temesgen, Saad S Kenderian, Andrew D Badley
Methods in Molecular Biology (Clifton, N.J.)|July 24, 2017
Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid LeukemiaSaad S Kenderian, Carl H June, Saar Gill
Clinical Hematology International|January 7, 2021
CART Cell Toxicities: New Insight into Mechanisms and ManagementAnas Zahid, Elizabeth L Siegler, Saad S Kenderian
Pageof 11